董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mary T. Szela | 女 | Director | 63 | 未披露 | 未持股 | 2026-05-28 |
| Graeme Bell | 男 | Director | 58 | 未披露 | 未持股 | 2026-05-28 |
| Ulrik Schulze | 男 | Director | 58 | 未披露 | 未持股 | 2026-05-28 |
| Akiko Moni Miyashita | 女 | Director | 70 | 未披露 | 未持股 | 2026-05-28 |
| David A. Berry | 男 | Chairman and Chief Executive Officer | 48 | 未披露 | 645.00 | 2026-05-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Alex Lau | 男 | Chief Financial Officer and Secretary | 40 | 未披露 | 未持股 | 2026-05-28 |
| David A. Berry | 男 | Chairman and Chief Executive Officer | 48 | 未披露 | 645.00 | 2026-05-28 |
董事简历
中英对照 | 中文 | 英文- Mary T. Szela
-
Mary T. Szela从2013年4月开始担任Melinta Therapeutics, Inc.的首席执行官，这是一家抗生素开发公司。她还从2013年1月开始担任Melinta的董事。在这之前，Szela女士于1987年加入美国雅培公司（Abbott Laboratories），并担任过几个领导职位，包括从2010年1月到2012年5月，担任全球战略营销部的高级副总裁，从2008年9月到2009年12月，担任美国制药部的高级副总裁。加入雅培前，Szela女士在伊利诺伊大学（University of Illinois）任职。她从2012年7月开始担任Suneva Medical, Inc.的董事。Szela女士在伊利诺伊大学（University of Illinois）获得护理学学士学位与工商管理硕士学位。
Mary T. Szela has served on board of directors since February 2026. Ms. Szela has served as Chief Executive Officer of TriSal Life Sciences, Inc. since January 2018. Ms. Szela also currently serves on the board of directors of TriSal Life Sciences, Inc., Absci Corporation, and Kura Oncology Inc. From January 2016 to November 2017, Ms. Szela served as Chief Executive Officer of Novelion Therapeutics Inc. (formerly Aegerion Pharmaceuticals, Inc.). From January 2013 to August 2015, Ms. Szela served as Chief Executive Officer of Melinta Therapeutics, Inc. During these roles, Ms. Szela led executive management, oversaw commercial and clinical operations, and managed corporate strategy. Earlier in her career, Ms. Szela spent more than 25 years at Abbott Laboratories, where she held a number of senior leadership positions. From 2010 to 2012, she served as Senior Vice President, Global Strategic Marketing and Services. From 2008 to 2010, she served as President, U.S. Pharmaceuticals. From 2002 to 2008, she served as Vice President, U.S. Commercial Operations. In these roles, Ms. Szela held responsibility for commercial operations, strategic planning, and biness development across multiple therapeutic areas. Ms. Szela has previoly served on the boards of directors of Senda Biosciences, Inc., Omega Therapeutics, Inc., Promethe Biosciences, Inc., Alimera Sciences, Inc., Coher BioSciences, Inc., Macrolide Pharmaceuticals, Inc., Novo Nordisk A/S, Receptos, Inc., and Suneva Medical, Inc. Ms. Szela received a Master of Biness Administration degree from the University of Illinois at the Chicago and a Bachelor of Science from the University of Illinois at Chicago College of Nursing. - Mary T. Szela从2013年4月开始担任Melinta Therapeutics, Inc.的首席执行官，这是一家抗生素开发公司。她还从2013年1月开始担任Melinta的董事。在这之前，Szela女士于1987年加入美国雅培公司（Abbott Laboratories），并担任过几个领导职位，包括从2010年1月到2012年5月，担任全球战略营销部的高级副总裁，从2008年9月到2009年12月，担任美国制药部的高级副总裁。加入雅培前，Szela女士在伊利诺伊大学（University of Illinois）任职。她从2012年7月开始担任Suneva Medical, Inc.的董事。Szela女士在伊利诺伊大学（University of Illinois）获得护理学学士学位与工商管理硕士学位。
- Mary T. Szela has served on board of directors since February 2026. Ms. Szela has served as Chief Executive Officer of TriSal Life Sciences, Inc. since January 2018. Ms. Szela also currently serves on the board of directors of TriSal Life Sciences, Inc., Absci Corporation, and Kura Oncology Inc. From January 2016 to November 2017, Ms. Szela served as Chief Executive Officer of Novelion Therapeutics Inc. (formerly Aegerion Pharmaceuticals, Inc.). From January 2013 to August 2015, Ms. Szela served as Chief Executive Officer of Melinta Therapeutics, Inc. During these roles, Ms. Szela led executive management, oversaw commercial and clinical operations, and managed corporate strategy. Earlier in her career, Ms. Szela spent more than 25 years at Abbott Laboratories, where she held a number of senior leadership positions. From 2010 to 2012, she served as Senior Vice President, Global Strategic Marketing and Services. From 2008 to 2010, she served as President, U.S. Pharmaceuticals. From 2002 to 2008, she served as Vice President, U.S. Commercial Operations. In these roles, Ms. Szela held responsibility for commercial operations, strategic planning, and biness development across multiple therapeutic areas. Ms. Szela has previoly served on the boards of directors of Senda Biosciences, Inc., Omega Therapeutics, Inc., Promethe Biosciences, Inc., Alimera Sciences, Inc., Coher BioSciences, Inc., Macrolide Pharmaceuticals, Inc., Novo Nordisk A/S, Receptos, Inc., and Suneva Medical, Inc. Ms. Szela received a Master of Biness Administration degree from the University of Illinois at the Chicago and a Bachelor of Science from the University of Illinois at Chicago College of Nursing.
- Graeme Bell
-
Graeme Bell，从1993年到2015年5月，他曾担任多种职务，并不断被提拔，包括副总裁，国家首席财务官，负责美国人类健康（从2010年到2015年5月）、全球医药连锁店总会计师（2009年至2010年）、英国国家首席财务官（2008年至2009年）、投资者关系全球主管（2004年至2008年）。他持有Durham University UK的工商管理硕士学位，也是the Chartered Institute of Management Accountants （CIMA）的成员。
Graeme Bell has served on board of directors since February 2026. Mr. Bell has served as Group Chief Financial Officer of Owkin, Inc. since May 2025. Owkin, Inc. is a private company with offices in London, Paris, New York and Boston that applies artificial intelligence and computational biology to biomedical research. He also serves as a member of the Board of Directors of Mindstate Design Labs Inc. since December 2025, as a member of the Board of Advisors of Symbiotix Health Ltd. since March 2025, and as a University Appointed Mentor at Loughborough University Science and Enterprise Park since September 2024. He is the Founder and Principal of ValueCycle LLC, an advisory and biness incubation firm serving biotechnology and pharmaceutical companies, and served as a member of the Board of Advisors of Raphael Labs Ltd. from June 2020 to May 2025. From August 2020 to September 2024, Mr. Bell held a series of senior executive roles at Valo Health Inc., a private biotechnology company founded by Flagship Pioneering Inc., including Interim President and Chief Executive Officer from January 2024 to September 2024, and Executive Vice President, Chief Operating Officer, Chief Financial Officer, and Chief Human Resources Officer from June 2020 to December 2023. At Valo Health Inc., he oversaw finance, treasury, tax, investor relations, audit, legal, biness development, human Resources and information technology, and led the company's capital formation and strategic partnership activities. From September 2018 to July 2020, Mr. Bell served as Executive Vice President and Chief Financial Officer of Tmunity Therapeutics Inc., a private biotherapeutics company developing engineered T cell therapies. From December 2016 to August 2018, he served as Executive Vice President and Chief Financial Officer of Intellia Therapeutics Inc. From June 2015 to October 2016, he served as Executive Vice President and Chief Financial Officer of Anacor Pharmaceuticals Inc., which was acquired by Pfizer Inc. in 2016. Mr. Bell spent over 20 years at Merck & Co., Inc. in roles of increasing responsibility, including Country Chief Financial Officer for U.S. Human Health, Head of Finance for Merck Sharp & Dohme Ltd. (U.K.), and Vice President and Head of Investor Relations. Mr. Bell has also served on the boards or advisory boards of Airmed LLC, Auravax LLC, ImmunoGenesis Inc., and CytoImmune Therapeutics Inc., and was previoly an Executive Advisor to ValueCycle LLC and a member of the Advisory Board of the Pennsylvania Interscholastic Cycling League. Mr. Bell received his M.B.A. in Finance and Marketing from Durham University Biness School (United Kingdom) and is a Fellow of the Chartered Institute of Management Accountants (FCMA). - Graeme Bell，从1993年到2015年5月，他曾担任多种职务，并不断被提拔，包括副总裁，国家首席财务官，负责美国人类健康（从2010年到2015年5月）、全球医药连锁店总会计师（2009年至2010年）、英国国家首席财务官（2008年至2009年）、投资者关系全球主管（2004年至2008年）。他持有Durham University UK的工商管理硕士学位，也是the Chartered Institute of Management Accountants （CIMA）的成员。
- Graeme Bell has served on board of directors since February 2026. Mr. Bell has served as Group Chief Financial Officer of Owkin, Inc. since May 2025. Owkin, Inc. is a private company with offices in London, Paris, New York and Boston that applies artificial intelligence and computational biology to biomedical research. He also serves as a member of the Board of Directors of Mindstate Design Labs Inc. since December 2025, as a member of the Board of Advisors of Symbiotix Health Ltd. since March 2025, and as a University Appointed Mentor at Loughborough University Science and Enterprise Park since September 2024. He is the Founder and Principal of ValueCycle LLC, an advisory and biness incubation firm serving biotechnology and pharmaceutical companies, and served as a member of the Board of Advisors of Raphael Labs Ltd. from June 2020 to May 2025. From August 2020 to September 2024, Mr. Bell held a series of senior executive roles at Valo Health Inc., a private biotechnology company founded by Flagship Pioneering Inc., including Interim President and Chief Executive Officer from January 2024 to September 2024, and Executive Vice President, Chief Operating Officer, Chief Financial Officer, and Chief Human Resources Officer from June 2020 to December 2023. At Valo Health Inc., he oversaw finance, treasury, tax, investor relations, audit, legal, biness development, human Resources and information technology, and led the company's capital formation and strategic partnership activities. From September 2018 to July 2020, Mr. Bell served as Executive Vice President and Chief Financial Officer of Tmunity Therapeutics Inc., a private biotherapeutics company developing engineered T cell therapies. From December 2016 to August 2018, he served as Executive Vice President and Chief Financial Officer of Intellia Therapeutics Inc. From June 2015 to October 2016, he served as Executive Vice President and Chief Financial Officer of Anacor Pharmaceuticals Inc., which was acquired by Pfizer Inc. in 2016. Mr. Bell spent over 20 years at Merck & Co., Inc. in roles of increasing responsibility, including Country Chief Financial Officer for U.S. Human Health, Head of Finance for Merck Sharp & Dohme Ltd. (U.K.), and Vice President and Head of Investor Relations. Mr. Bell has also served on the boards or advisory boards of Airmed LLC, Auravax LLC, ImmunoGenesis Inc., and CytoImmune Therapeutics Inc., and was previoly an Executive Advisor to ValueCycle LLC and a member of the Advisory Board of the Pennsylvania Interscholastic Cycling League. Mr. Bell received his M.B.A. in Finance and Marketing from Durham University Biness School (United Kingdom) and is a Fellow of the Chartered Institute of Management Accountants (FCMA).
- Ulrik Schulze
-
Ulrik Schulze是Sanrigen GmbH的董事总经理兼董事长，该公司是一家专门为生命科学公司提供战略和运营咨询的瑞士咨询公司。他还担任波士顿咨询公司（瑞士）的高级顾问以及BioVersys AG（SIX：BIOV）的非执行董事和审计委员会成员、Biograil AP的非执行董事以及Indivi AG的非执行董事。Schulze先生是Averin Capital的顾问，也是Averin Health Opportunities Fund I的有限合伙人。从2021年10月至2023年11月，Schulze先生担任ReproNovo SA的董事长，该公司是一家私人控股的瑞士生物技术公司。他曾担任波士顿咨询公司的董事总经理和高级合伙人，在那里他领导了BCG的全球生物制药部门，并就战略向领先的制药、生物技术和私募股权公司提供建议。Schulze先生在生物技术、医疗保健战略和财务顾问方面拥有超过25年的经验，包括在瑞士六大交易所上市的一家上市公司担任董事会和审计委员会领导职务。Schulze先生拥有化学工程硕士学位和生物技术博士学位，均来自丹麦技术大学。
Ulrik Schulze has served on board of directors since February 2026. Mr. Schulze is the Managing Director and Chairman of Sanrigen GmbH, a Swiss advisory firm specializing in strategic and operational consulting for life science companies. He also serves as a Senior Advisor to The Boston Consulting Group (Switzerland) and as a Non Executive Director and member of the Audit Committee of BioVersys AG (SIX: BIOV), a Non Executive Director of Biograil Aps, and a Non Executive Director of Indivi AG. Mr. Schulze is an Advisor to Averin Capital and a limited partner in Averin Health Opportunities Fund I. From October 2021 to November 2023, Mr. Schulze served as Chairman of ReproNovo SA, a privately held Swiss biotechnology company. He was previoly a Managing Director and Senior Partner at The Boston Consulting Group, where he led the global Biopharma Sector for BCG and advised leading pharma, biotech and private equity companies on strategy. Mr. Schulze has more than 25 years of experience in biotechnology, healthcare strategy, and financial advisory roles, including board and audit committee leadership at a public company listed on the SIX Swiss Exchange. Mr. Schulze holds an M.Sc. in Chemical Engineering and a Ph.D. in Biotechnology, both from the Technical University of Denmark. - Ulrik Schulze是Sanrigen GmbH的董事总经理兼董事长，该公司是一家专门为生命科学公司提供战略和运营咨询的瑞士咨询公司。他还担任波士顿咨询公司（瑞士）的高级顾问以及BioVersys AG（SIX：BIOV）的非执行董事和审计委员会成员、Biograil AP的非执行董事以及Indivi AG的非执行董事。Schulze先生是Averin Capital的顾问，也是Averin Health Opportunities Fund I的有限合伙人。从2021年10月至2023年11月，Schulze先生担任ReproNovo SA的董事长，该公司是一家私人控股的瑞士生物技术公司。他曾担任波士顿咨询公司的董事总经理和高级合伙人，在那里他领导了BCG的全球生物制药部门，并就战略向领先的制药、生物技术和私募股权公司提供建议。Schulze先生在生物技术、医疗保健战略和财务顾问方面拥有超过25年的经验，包括在瑞士六大交易所上市的一家上市公司担任董事会和审计委员会领导职务。Schulze先生拥有化学工程硕士学位和生物技术博士学位，均来自丹麦技术大学。
- Ulrik Schulze has served on board of directors since February 2026. Mr. Schulze is the Managing Director and Chairman of Sanrigen GmbH, a Swiss advisory firm specializing in strategic and operational consulting for life science companies. He also serves as a Senior Advisor to The Boston Consulting Group (Switzerland) and as a Non Executive Director and member of the Audit Committee of BioVersys AG (SIX: BIOV), a Non Executive Director of Biograil Aps, and a Non Executive Director of Indivi AG. Mr. Schulze is an Advisor to Averin Capital and a limited partner in Averin Health Opportunities Fund I. From October 2021 to November 2023, Mr. Schulze served as Chairman of ReproNovo SA, a privately held Swiss biotechnology company. He was previoly a Managing Director and Senior Partner at The Boston Consulting Group, where he led the global Biopharma Sector for BCG and advised leading pharma, biotech and private equity companies on strategy. Mr. Schulze has more than 25 years of experience in biotechnology, healthcare strategy, and financial advisory roles, including board and audit committee leadership at a public company listed on the SIX Swiss Exchange. Mr. Schulze holds an M.Sc. in Chemical Engineering and a Ph.D. in Biotechnology, both from the Technical University of Denmark.
- Akiko Moni Miyashita
-
Akiko Moni Miyashita Akiko Moni Miyashita是Beacon Hill Strategy Group的创始人，她自2024年10月以来一直担任该职位，负责就增长战略、并购和人工智能推动的转型向首席执行官和董事会提供建议。她此前曾于2022年5月至2026年5月在生物技术上市公司Halozyme Therapeutics, Inc.的董事会任职。Miyashita女士在战略、财务和企业发展方面拥有超过25年的经验，在医疗保健和生命科学、技术和全球市场方面拥有专长。Miyashita女士曾于2019年5月至2024年9月担任AI原生药物发现和开发公司Valo Health，LLC的执行副总裁兼首席战略官，负责领导公司战略，包括商业模式开发、战略规划、资本分配和战略交易。在加入Valo Health，LLC之前，Miyashita女士于2011年10月至2015年9月担任麦肯锡公司的高级顾问，并于2015年8月至2019年8月担任Innosight LLC的合伙人，在那里她就战略、增长和并购向首席执行官和执行团队提供建议。从2003年7月到2011年10月，Miyashita女士在IBM担任企业发展副总裁，在那里她领导了从战略到整合的并购活动，以及跨越全球市场的战略合作伙伴关系和风险投资。
Akiko Moni Miyashita Akiko Moni Miyashita, is the Founder of Beacon Hill Strategy Group, a position she has held since October 2024, where she advises chief executive officers and boards of directors on growth strategy, mergers and acquisitions, and AI enabled transformation. She previously served on the board of directors of Halozyme Therapeutics, Inc., a publicly traded biotechnology company, from May 2022 to May 2026. Ms. Miyashita has over 25 years of experience across strategy, finance and corporate development, with expertise in healthcare and life sciences, technology and global markets. Ms. Miyashita previously served as Executive Vice President and Chief Strategy Officer of Valo Health, LLC an AI native drug discovery and development company, from May 2019 to September 2024, where she led corporate strategy, including business model development, strategic planning, capital allocation and strategic transactions. Prior to Valo Health, LLC, Ms. Miyashita served as a Senior Advisor at McKinsey & Company, Inc. from October 2011 to September 2015 and as a Partner at Innosight LLC from August 2015 to August 2019, where she advised chief executive officers and executive teams on strategy, growth and mergers and acquisitions. From July 2003 through October 2011, Ms. Miyashita served as Vice President of Corporate Development at IBM where she led mergers and acquisitions from strategy through integration, as well as strategic partnerships and venture investments across global markets. - Akiko Moni Miyashita Akiko Moni Miyashita是Beacon Hill Strategy Group的创始人，她自2024年10月以来一直担任该职位，负责就增长战略、并购和人工智能推动的转型向首席执行官和董事会提供建议。她此前曾于2022年5月至2026年5月在生物技术上市公司Halozyme Therapeutics, Inc.的董事会任职。Miyashita女士在战略、财务和企业发展方面拥有超过25年的经验，在医疗保健和生命科学、技术和全球市场方面拥有专长。Miyashita女士曾于2019年5月至2024年9月担任AI原生药物发现和开发公司Valo Health，LLC的执行副总裁兼首席战略官，负责领导公司战略，包括商业模式开发、战略规划、资本分配和战略交易。在加入Valo Health，LLC之前，Miyashita女士于2011年10月至2015年9月担任麦肯锡公司的高级顾问，并于2015年8月至2019年8月担任Innosight LLC的合伙人，在那里她就战略、增长和并购向首席执行官和执行团队提供建议。从2003年7月到2011年10月，Miyashita女士在IBM担任企业发展副总裁，在那里她领导了从战略到整合的并购活动，以及跨越全球市场的战略合作伙伴关系和风险投资。
- Akiko Moni Miyashita Akiko Moni Miyashita, is the Founder of Beacon Hill Strategy Group, a position she has held since October 2024, where she advises chief executive officers and boards of directors on growth strategy, mergers and acquisitions, and AI enabled transformation. She previously served on the board of directors of Halozyme Therapeutics, Inc., a publicly traded biotechnology company, from May 2022 to May 2026. Ms. Miyashita has over 25 years of experience across strategy, finance and corporate development, with expertise in healthcare and life sciences, technology and global markets. Ms. Miyashita previously served as Executive Vice President and Chief Strategy Officer of Valo Health, LLC an AI native drug discovery and development company, from May 2019 to September 2024, where she led corporate strategy, including business model development, strategic planning, capital allocation and strategic transactions. Prior to Valo Health, LLC, Ms. Miyashita served as a Senior Advisor at McKinsey & Company, Inc. from October 2011 to September 2015 and as a Partner at Innosight LLC from August 2015 to August 2019, where she advised chief executive officers and executive teams on strategy, growth and mergers and acquisitions. From July 2003 through October 2011, Ms. Miyashita served as Vice President of Corporate Development at IBM where she led mergers and acquisitions from strategy through integration, as well as strategic partnerships and venture investments across global markets.
- David A. Berry
-
David A. Berry自2009年8月担任公司董事。自2005年以来，任职于 with Flagship Ventures ，并从2008年以来一直任合伙人。他获得麻省理工学院学士学位和博士学位。以及哈佛医学院医学博士学位。
David A. Berry has served on board of directors since October 2025. Dr. Berry is the co founder of Averin Capital, where he has been serving as a Managing Partner since May 2025, and the Chairman and CEO of Averin Capital Acquisition Corp., a special purpose acquisition company (Nasdaq: ACAA). In February 2026, Dr. Berry joined the board of directors of Common Clinic. Previoly, Dr. Berry served as a Partner from 2008 to 2015, and as a General Partner from 2015 to May 2025, at Flagship Pioneering, where he worked from November 2005 to January 2026. Dr. Berry was previoly founder and CEO of Valo Health where he served on the board from October 2018 through January 2024. He served on the board of directors of Omega Therapeutics, Inc (Nasdaq: OMGA) from August 2017 to June 2022. He also served as a director of Seres Therapeutics, Inc. (Nasdaq: MCRB) from September 2012 to July 2016, and served as its CEO from 2012 to 2014. Dr. Berry also served as the Chief Executive Officer and as a member of the board of directors of Axcella Health, Inc. (Nasdaq: AXLA) from September 2009 until May 2020, and as Chief Executive Officer and as a member of the board of Evelo Biosciences (Nasdaq: EVLO) from May 2014 to February 2018. He holds an M.D. from Harvard Medical School, a Ph.D. in biological engineering from the Massachetts Institute of Technology, and a B.S. in brain and cognitive sciences from the Massachetts Institute of Technology. - David A. Berry自2009年8月担任公司董事。自2005年以来，任职于 with Flagship Ventures ，并从2008年以来一直任合伙人。他获得麻省理工学院学士学位和博士学位。以及哈佛医学院医学博士学位。
- David A. Berry has served on board of directors since October 2025. Dr. Berry is the co founder of Averin Capital, where he has been serving as a Managing Partner since May 2025, and the Chairman and CEO of Averin Capital Acquisition Corp., a special purpose acquisition company (Nasdaq: ACAA). In February 2026, Dr. Berry joined the board of directors of Common Clinic. Previoly, Dr. Berry served as a Partner from 2008 to 2015, and as a General Partner from 2015 to May 2025, at Flagship Pioneering, where he worked from November 2005 to January 2026. Dr. Berry was previoly founder and CEO of Valo Health where he served on the board from October 2018 through January 2024. He served on the board of directors of Omega Therapeutics, Inc (Nasdaq: OMGA) from August 2017 to June 2022. He also served as a director of Seres Therapeutics, Inc. (Nasdaq: MCRB) from September 2012 to July 2016, and served as its CEO from 2012 to 2014. Dr. Berry also served as the Chief Executive Officer and as a member of the board of directors of Axcella Health, Inc. (Nasdaq: AXLA) from September 2009 until May 2020, and as Chief Executive Officer and as a member of the board of Evelo Biosciences (Nasdaq: EVLO) from May 2014 to February 2018. He holds an M.D. from Harvard Medical School, a Ph.D. in biological engineering from the Massachetts Institute of Technology, and a B.S. in brain and cognitive sciences from the Massachetts Institute of Technology.
高管简历
中英对照 | 中文 | 英文- Alex Lau
Alex Lau自2025年10月21日起担任首席财务官兼秘书。刘先生自2025年2月起担任Averin Capital的合伙人兼运营主管，负责财务、投资者关系、合规和公司运营。2014年10月至2025年1月，刘先生在OpenView Venture Partners担任运营和财务领导职务，最近担任运营合伙人。刘先生拥有本特利大学金融学学士学位和波士顿学院工商管理硕士学位。
Alex Lau has been Chief Financial Officer and Secretary since October 21, 2025. Mr. Lau has served as Partner and Head of Operations at Averin Capital since February 2025, where he leads finance, investor relations, compliance, and firm operations. From October 2014 to January 2025, Mr. Lau held operations and finance leadership roles at OpenView Venture Partners, most recently as Partner, Operations. Mr. Lau holds a B.S. in Finance from Bentley University and an M.B.A. from Boston College.- Alex Lau自2025年10月21日起担任首席财务官兼秘书。刘先生自2025年2月起担任Averin Capital的合伙人兼运营主管，负责财务、投资者关系、合规和公司运营。2014年10月至2025年1月，刘先生在OpenView Venture Partners担任运营和财务领导职务，最近担任运营合伙人。刘先生拥有本特利大学金融学学士学位和波士顿学院工商管理硕士学位。
- Alex Lau has been Chief Financial Officer and Secretary since October 21, 2025. Mr. Lau has served as Partner and Head of Operations at Averin Capital since February 2025, where he leads finance, investor relations, compliance, and firm operations. From October 2014 to January 2025, Mr. Lau held operations and finance leadership roles at OpenView Venture Partners, most recently as Partner, Operations. Mr. Lau holds a B.S. in Finance from Bentley University and an M.B.A. from Boston College.
- David A. Berry
David A. Berry自2009年8月担任公司董事。自2005年以来，任职于 with Flagship Ventures ，并从2008年以来一直任合伙人。他获得麻省理工学院学士学位和博士学位。以及哈佛医学院医学博士学位。
David A. Berry has served on board of directors since October 2025. Dr. Berry is the co founder of Averin Capital, where he has been serving as a Managing Partner since May 2025, and the Chairman and CEO of Averin Capital Acquisition Corp., a special purpose acquisition company (Nasdaq: ACAA). In February 2026, Dr. Berry joined the board of directors of Common Clinic. Previoly, Dr. Berry served as a Partner from 2008 to 2015, and as a General Partner from 2015 to May 2025, at Flagship Pioneering, where he worked from November 2005 to January 2026. Dr. Berry was previoly founder and CEO of Valo Health where he served on the board from October 2018 through January 2024. He served on the board of directors of Omega Therapeutics, Inc (Nasdaq: OMGA) from August 2017 to June 2022. He also served as a director of Seres Therapeutics, Inc. (Nasdaq: MCRB) from September 2012 to July 2016, and served as its CEO from 2012 to 2014. Dr. Berry also served as the Chief Executive Officer and as a member of the board of directors of Axcella Health, Inc. (Nasdaq: AXLA) from September 2009 until May 2020, and as Chief Executive Officer and as a member of the board of Evelo Biosciences (Nasdaq: EVLO) from May 2014 to February 2018. He holds an M.D. from Harvard Medical School, a Ph.D. in biological engineering from the Massachetts Institute of Technology, and a B.S. in brain and cognitive sciences from the Massachetts Institute of Technology.- David A. Berry自2009年8月担任公司董事。自2005年以来，任职于 with Flagship Ventures ，并从2008年以来一直任合伙人。他获得麻省理工学院学士学位和博士学位。以及哈佛医学院医学博士学位。
- David A. Berry has served on board of directors since October 2025. Dr. Berry is the co founder of Averin Capital, where he has been serving as a Managing Partner since May 2025, and the Chairman and CEO of Averin Capital Acquisition Corp., a special purpose acquisition company (Nasdaq: ACAA). In February 2026, Dr. Berry joined the board of directors of Common Clinic. Previoly, Dr. Berry served as a Partner from 2008 to 2015, and as a General Partner from 2015 to May 2025, at Flagship Pioneering, where he worked from November 2005 to January 2026. Dr. Berry was previoly founder and CEO of Valo Health where he served on the board from October 2018 through January 2024. He served on the board of directors of Omega Therapeutics, Inc (Nasdaq: OMGA) from August 2017 to June 2022. He also served as a director of Seres Therapeutics, Inc. (Nasdaq: MCRB) from September 2012 to July 2016, and served as its CEO from 2012 to 2014. Dr. Berry also served as the Chief Executive Officer and as a member of the board of directors of Axcella Health, Inc. (Nasdaq: AXLA) from September 2009 until May 2020, and as Chief Executive Officer and as a member of the board of Evelo Biosciences (Nasdaq: EVLO) from May 2014 to February 2018. He holds an M.D. from Harvard Medical School, a Ph.D. in biological engineering from the Massachetts Institute of Technology, and a B.S. in brain and cognitive sciences from the Massachetts Institute of Technology.